Results from Phase 2 Studies of Oral Ozanimod in Crohn’s Disease and U
In the STEPSTONE open-label study, ozanimod demonstrated meaningful clinical...
2017-10-17
文传商讯
FASLODEX (FULVESTRANT) RECEIVES POSITIVE CHMP OPINION FOR THE TREATMENT
Positive opinion is based on Phase III trial data demonstrating a 4.9 month ...
2017-10-17
文传商讯
IPF World Week 2017: Boehringer Ingelheim helps healthcare professional
• Even though progress has been made, diagnosis of idiopathic pulmonary...
2017-09-19
文传商讯
Boehringer Ingelheim and Gubra collaborate to develop next generation o
Obesity affects more than half a billion people worldwide and is a leading r...
2017-09-09
文传商讯
Phase 2a Safety and Efficacy Data Support Further Development of Oral C
Data showed positive trend in multiple disease measures versus placebo Resu...
2017-06-16
文传商讯
Oral GED-0301 Phase 1b Results Show Clinical Remission and Endoscopic R
Clinical improvement observed early, with highest clinical response and remi...
2016-10-17
文传商讯
Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic
INGELHEIM, Germany -- (BUSINESS WIRE) --Boehringer Ingelheim today announced...
2016-09-13
文传商讯
INMARKTM now enrolling: first study to evaluate the effect of OFEV (nin
First time the effect of OFEV® is being explored on change of biomarkers...
2016-07-01
文传商讯
IL-23 inhibitor risankizumab induces remission in Phase II study in pat
After 12 weeks, approximately twice as many patients with moderate-to-severe...
2016-05-26
文传商讯
New Presentations at ATS 2016 Reinforce OFEV (nintedanib) Efficacy, Saf
A new analysis of Phase III INPULSIS® trials reinforces OFEV®’...
2016-05-18
文传商讯
